参考资料：
[1] Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan. Retrieved November 26, 2019, from https://www.businesswire.com/news/home/20191125005733/en
[2] Poxel Corporate Presentation. Retrieved November 26, 2019, from https://d1io3yog0oux5.cloudfront.net/_43b6a731147fdf489f58a348c3b4ae6a/poxelpharma/db/373/3167/pdf/Poxel_Corporate+Presentation+_October+2019_.pdf
*声明：本文由入驻新浪医药新闻作者撰写，观点仅代表作者本人，不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
佐力乌灵胶囊助力高
如何改善失眠困扰
BOE（京东方）亮相